Direct probe sensed temperature method for speed change for heat sensitive portions of a thermokinetically melt blended batch
09821283 · 2017-11-21
Assignee
Inventors
Cpc classification
B01F27/052
PERFORMING OPERATIONS; TRANSPORTING
A61J3/07
HUMAN NECESSITIES
B01F27/071
PERFORMING OPERATIONS; TRANSPORTING
B01F35/214
PERFORMING OPERATIONS; TRANSPORTING
B01F2101/22
PERFORMING OPERATIONS; TRANSPORTING
B01F27/112
PERFORMING OPERATIONS; TRANSPORTING
B01F27/0724
PERFORMING OPERATIONS; TRANSPORTING
B01F35/2209
PERFORMING OPERATIONS; TRANSPORTING
B01F35/213
PERFORMING OPERATIONS; TRANSPORTING
International classification
Abstract
The present disclosure provides for a first embodiment, where, a first, lower shaft speed mixing of the component combination takes place in a thermokinetic mixer, where monitoring of the batch by temperature rate increase determination results in a determination that a substantial portion of desired thermokinetic mixing has occurred, whereafter a different shaft speed is used to complete the desired thermokinetic mixing of the component combination.
Claims
1. A method of thermokinetic mixing of a component combination comprising at least one active pharmaceutical ingredient and at least one excipient or carrier comprising: (a) a thermokinetic mixer having a mixing chamber, where the mixing chamber contains thermokinetic extensions on a motor shaft and that motor shaft extends to a shaft motor, whose rate of rotation speed is controlled by a mixer control microprocessor; (b) adding a batch of the component combination to the mixing chamber; (c) thermokinetic mixing of the component combination wherein: i. the rate of rotation speed of the motor shaft and the temperature of the batch both increase during a first stage period, ii. an average temperature of the batch is periodically detected at a trigger data sensor, and iii. average temperature data is delivered to the mixer controller microprocessor, where a temperature increase rate is calculated and compared with a pre-determined temperature increase rate trigger setpoint; and (d) when a current temperature increase rate equals or is less than the trigger setpoint, the mixer control microprocessor operates to change the rate of rotation speed of the motor shaft for a second stage period.
2. The method of claim 1, wherein the temperature increase rate is calculated by averaging a certain number of last stored values of the average temperature data.
3. The method of claim 1, wherein the rotation speed of the motor shaft is maintained at the same speed as the rotation speed at the trigger setpoint for a pre-determined period of time, after which the batch is ejected from the mixing chamber.
4. The method of claim 3, wherein crystallinity of the batch is measured by Raman spectroscopy.
5. The method of claim 1, wherein the rotation speed of the motor shaft is reduced in the second stage period for a pre-determined period of time, after which the batch is ejected from the mixing chamber.
6. The method of claim 5, wherein crystallinity of the batch is measured by Raman spectroscopy.
7. The method of claim 1, wherein the rotation speed of the motor shaft is increased in the second stage period, an average temperature of the batch is periodically detected at a trigger data sensor during the second stage period, average temperature data is delivered to the mixer controller microprocessor, where a temperature increase rate is calculated and compared with a pre-determined second temperature increase rate trigger setpoint, and when a current temperature rate increase equals or is less than the second trigger setpoint, the batch is ejected from the mixing chamber.
8. The method of claim 7, wherein crystallinity of the batch is measured by Raman spectroscopy.
9. The method of claim 7, wherein the second temperature increase rate trigger setpoint is calculated by first obtaining a maximum of an average of a certain number of previously stored values of temperature increase rates over a previous time period and then reducing that average by a pre-determined percentage.
10. The method of claim 1, wherein the rotation speed of the motor shaft is increased in the second stage period, an average temperature of the batch is periodically detected at a trigger data sensor during the second stage period, average temperature data is delivered to the mixer controller microprocessor, where a temperature increase rate is calculated and compared with a pre-determined second temperature increase rate trigger setpoint, wherein the rotation speed of the motor shaft is maintained at the same speed as the rotation speed at the second trigger setpoint for a pre-determined period of time, after which the batch is ejected from the mixing chamber.
11. The method of claim 10, wherein crystallinity of the batch is measured by Raman spectroscopy.
12. The method of claim 10, wherein the second temperature increase rate trigger setpoint is calculated by first obtaining a maximum of an average of a certain number of previously stored values of temperature increase rates over a previous time period and then reducing that average by a pre-determined percentage.
13. The method of claim 1, wherein the temperature increase rate trigger setpoint is calculated by first obtaining a maximum of an average of a certain number of previously stored values of temperature increase rates over a previous time period and then reducing that average by a pre-determined percentage.
14. The method of claim 1, wherein the trigger setpoint is from 20 to 0 degrees F. or C. per second.
15. The method of claim 11, wherein the trigger setpoint is from 15 to 0 degrees F. or C. per second.
16. The method of claim 12, wherein the trigger setpoint is from 5 to 0 degrees F. or C. per second.
17. A method of thermokinetic mixing of a component combination comprising at least one active pharmaceutical ingredient and at least one excipient or carrier comprising: (a) a thermokinetic mixer having a mixing chamber, where the mixing chamber contains thermokinetic extensions on a motor shaft and that motor shaft extends to a shaft motor, whose rotation speed is controlled by a mixer control microprocessor; (b) adding a batch of the component combination to the mixing chamber; (c) thermokinetic mixing of the component combination wherein: i. the temperature of the batch increases during a first stage period, ii. crystallinity of the batch is periodically detected at a trigger data sensor, and iii. crystallinity data is delivered to the mixer controller microprocessor, where a current value of the crystallinity data is compared with a pre-determined crystallinity value trigger setpoint; and (d) when current crystallinity data equals or is less than the trigger setpoint, the batch is ejected from the mixing chamber.
18. The method of claim 17, wherein crystallinity is measured by Raman spectroscopy.
19. The method of claim 18, wherein the trigger data sensor is a relatively narrow tube comprising a distal end and a proximal end, where the distal end comprises at least one lens and a laser which is directed into a sample space of the thermokinetically mixing batch.
20. The method of claim 19, wherein sensed emissions of the sample space are transmitted to a Raman spectroscope, whereat a detected crystallinity of a batch crystalline component is calculated and transmitted to the mixer control microprocessor.
21. A method of thermokinetic mixing of a component combination comprising at least one active pharmaceutical ingredient and at least one excipient or carrier comprising: (a) a thermokinetic mixer having a mixing chamber, where the mixing chamber contains thermokinetic extensions on a motor shaft and that motor shaft extends to a shaft motor, whose rate of rotation speed is controlled by a mixer control microprocessor; (b) adding a batch of the component combination to the mixing chamber; (c) thermokinetic mixing of the component combination wherein: i. the temperature of the batch increases during a first stage period, ii. crystalline to amorphous transformation data of the batch is periodically detected at a trigger data sensor, and iii. crystalline to amorphous transformation data is delivered to the mixer controller microprocessor, where a current value of the crystalline to amorphous transformation data is compared with a pre-determined crystalline to amorphous transformation value trigger setpoint; and (d) when current crystalline to amorphous transformation data equals or is less than the trigger setpoint, the batch is ejected from the mixing chamber.
22. The method of claim 21, wherein crystallinity of the batch is measured by Raman spectroscopy.
Description
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
(1) The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
DETAILED DESCRIPTION OF THE INVENTION
(29) Although making and using various embodiments of the present disclosure are discussed in detail below, it should be appreciated that the present disclosure provides many inventive concepts that may be embodied in a wide variety of contexts. The specific aspects and embodiments discussed herein are merely illustrative of ways to make and use the disclosure, and do not limit the scope of the disclosure.
(30) To facilitate the understanding of this disclosure, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present disclosure. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. With regard to the values or ranges recited herein, the term “about” is intended to to capture variations above and below the stated number that may achieve substantially the same results as the stated number. In the present disclosure, each of the variously stated ranges is intended to be continuous so as to include each numerical parameter between the stated minimum and maximum value of each range. For Example, a range of about 1 to about 4 includes about 1, 1, about 2, 2, about 3, 3, about 4, and 4. The terminology herein is used to describe specific embodiments of the disclosure, but their usage does not delimit the disclosure, except as outlined in the claims.
(31) As used herein, the term “thermokinetic compounding” or “TKC” refers to a method of thermokinetic mixing until melt blended. TKC may also be described as a thermokinetic mixing process in which processing ends at a point sometime prior to agglomeration.
(32) As used herein, the term “main facial portion” refers to the “top face” of a shaft extension. The top face of a shaft extension is the face facing the inside wall of the mixing chamber of a thermokinetic mixer.
(33) As used herein, the term “shear transition temperature” refers to the point at which further energy input does not result in an immediate rise in temperature.
(34) As used herein, the phrase “a homogenous, heterogenous, or heterogeneously homogenous composite or an amorphous composite” refers to the various compositions that can be made using the TKC method.
(35) As used herein, the term “heterogeneously homogeneous composition” refers to a material composition having at least two different materials that are evenly and uniformly distributed throughout the volume.
(36) As used herein, “bioavailability” is a term meaning the degree to which a drug becomes available to the target tissue after being administered to the body. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is not highly soluble. In certain embodiments such as formulations of proteins, the proteins may be water soluble, poorly soluble, not highly soluble, or not soluble. The skilled artisan will recognize that various methodologies may be used to increase the solubility of proteins, e.g., use of different solvents, excipients, carriers, formation of fusion proteins, targeted manipulation of the amino acid sequence, glycosylation, lipidation, degradation, combination with one or more salts and the addition of various salts.
(37) As used herein, the phrase “pharmaceutically acceptable” refers to molecular entities, compositions, materials, excipients, carriers, and the like that do not produce an allergic or similar untoward reaction when administered to humans in general.
(38) As used herein, the term “active pharmaceutical ingredient” or “API” is interchangeable with the terms “drug,” “drug product,” “medication,” “liquid,” “biologic,” or “active ingredient.” As used herein, an “API” is any component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans or other animals. In certain embodiments, the aqueous solubility of the API may be poorly soluble.
(39) Examples of APIs that may be utilized in the present disclosure include, but are not limited to, antibiotics, analgesics, vaccines, anticonvulsants, anti-diabetic agents, anti-fungal agents, anti-neoplastic agents, anti-parkinsonian agents, anti-rheumatic agents, appetite suppressants, biological response modifiers, cardiovascular agents, central nervous system stimulants, contraceptive agents, dietary supplements, vitamins, minerals, lipids, saccharides, metals, amino acids (and precursors), nucleic acids and precursors, contrast agents, diagnostic agents, dopamine receptor agonists, erectile dysfunction agents, fertility agents, gastrointestinal agents, hormones, immunomodulators, anti-hypercalcemia agents, mast cell stabilizers, muscle relaxants, nutritional agents, ophthalmic agents, osteoporosis agents, psychotherapeutic agents, parasympathomimetic agents, parasympatholytic agents, respiratory agents, sedative hypnotic agents, skin and mucous membrane agents, smoking cessation agents, steroids, sympatholytic agents, urinary tract agents, uterine relaxants, vaginal agents, vasodilator, anti-hypertensive, hyperthyroids, anti-hyperthyroids, anti-asthmatics and vertigo agents. In certain embodiments, the API is a poorly water-soluble drug or a drug with a high melting point.
(40) The API may be found in the form of one or more pharmaceutically acceptable salts, esters, derivatives, analogs, prodrugs, and solvates thereof. As used herein, a “pharmaceutically acceptable salt” is understood to mean a compound formed by the interaction of an acid and a base, the hydrogen atoms of the acid being replaced by the positive ion of the base. Non-limiting examples of pharmaceutically acceptable salts include sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate. Another method for defining the ionic salts may be as an acidic functional group, such as a carboxylic acid functional group, and a pharmaceutically acceptable inorganic or organic base. Non-limiting examples of bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium and lithium; hydroxides of calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia; and organic amines, such as unsubstituted or hydroxy substituted mono-, di-, or trialkylamines; dicyclohexylamine; tributylamine; pyridine; N-methyl-N-ethylamine; diethylamine; triethylamine; mono-, bis- or tris-(2-hydroxy-lower alkyl amines), such as mono- bis- or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxy lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine, or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.
(41) A variety of administration routes are available for delivering the APIs to a patient in need. The particular route selected will depend upon the particular drug selected, the weight and age of the patient, and the dosage required for therapeutic effect. The pharmaceutical compositions may conveniently be presented in unit dosage form. The APIs suitable for use in accordance with the present disclosure, and their pharmaceutically acceptable salts, derivatives, analogs, prodrugs, and solvates thereof, can be administered alone, but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent, or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
(42) The APIs may be used in a variety of application modalities, including oral delivery as tablets, capsules or suspensions; pulmonary and nasal delivery; topical delivery as emulsions, ointments or creams; transdermal delivery; and parenteral delivery as suspensions, microemulsions or depot. As used herein, the term “parenteral” includes subcutaneous, intravenous, intramuscular, or infusion routes of administration.
(43) The excipients and adjuvants that may be used in the presently disclosed compositions and composites, while potentially having some activity in their own right, for example, antioxidants, are generally defined for this application as compounds that enhance the efficiency and/or efficacy of the active ingredients. It is also possible to have more than one active ingredient in a given solution, so that the particles formed contain more than one active ingredient.
(44) As stated, excipients and adjuvants may be used to enhance the efficacy and efficiency of the APIs. Non-limiting examples of compounds that can be included are binders, cryoprotectants, lyoprotectants, surfactants, fillers, stabilizers, polymers, protease inhibitors, antioxidants and absorption enhancers. The excipients may be chosen to modify the intended function of the active ingredient by improving flow, or bio-availability, or to control or delay the release of the API. Specific nonlimiting examples include: sucrose, trehaolose, Span 80, Tween 80, Brij 35, Brij 98, Pluronic, sucroester 7, sucroester 11, sucroester 15, sodium lauryl sulfate, oleic acid, laureth-9, laureth-8, lauric acid, vitamin E TPGS, Gelucire 50/13, Gelucire 53/10, Labrafil, dipalmitoyl phosphadityl choline, glycolic acid and salts, deoxycholic acid and salts, sodium fusidate, cyclodextrins, polyethylene glycols, labrasol, polyvinyl alcohols, polyvinyl pyrrolidones and tyloxapol. Using the process of the present disclosure, the morphology of the active ingredients can be modified, resulting in highly porous microparticles and nanoparticles.
(45) Exemplary thermal binders that may be used in the presently disclosed compositions and composites include but are not limited to polyethylene oxide; polypropylene oxide; polyvinylpyrrolidone; polyvinylpyrrolidone-co-vinylacetate; acrylate and methacrylate copolymers; polyethylene; polycaprolactone; polyethylene-co-polypropylene; alkylcelluloses such as methylcellulose; hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxybutylcellulose; hydroxyalkyl al kylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose; starches, pectins; polysaccharides such as tragacanth, gum arabic, guar gum, and xanthan gum. One embodiment of the binder is poly(ethylene oxide) (PEO), which can be purchased commercially from companies such as the Dow Chemical Company, which markets PEO under the POLY OX™ trademark exemplary grades of which can include WSR N80 having an average molecular weight of about 200,000; 1,000,000; and 2,000,000.
(46) Suitable grades of PEO can also be characterized by viscosity of solutions containing fixed concentrations of PEO, such as for example:
(47) TABLE-US-00001 Viscosity Range POLYOX Aqueous Solution Water-Soluble Resin NF at 25° C., mPa .Math. s POLYOX Water-Soluble Resin 30-50 NF WSR N-10 (5% solution) POLYOX Water-Soluble Resin 55-90 NF WSR N-80 (5% solution) POLYOX Water-Soluble Resin 600-1,200 NF WSR N-750 (5% solution) POLYOX Water-Soluble Resin 4,500-8,800 NF WSR-205 (5% solution) POLYOX Water-Soluble Resin 8,800-17,600 NF WSR-1105 (5% solution) POLYOX Water-Soluble Resin 400-800 NF WSR N-12K (2% solution) POLYOX Water-Soluble Resin 2,000-4,000 NF WSR N-60K (2% solution) POLYOX Water-Soluble Resin 1,650-5,500 NF WSR-301 (1% solution) POLYOX Water-Soluble Resin 5,500-7,500 NF WSR Coagulant (1% solution) POLYOX Water-Soluble Resin 7,500-10,000 NF WSR-303 (1% solution)
(48) Suitable thermal binders that may or may not require a plasticizer include, for example, Eudragit™ RS PO, Eudragit™ S100, Kollidon SR (poly(vinyl acetate)-co-poly(vinylpyrrolidone) copolymer), Ethocel™ (ethylcellulose), HPC (hydroxypropylcellulose), cellulose acetate butyrate, poly(vinylpyrrolidone) (PVP), poly(ethylene glycol) (PEG), poly(ethylene oxide) (PEO), poly(vinyl alcohol) (PVA), hydroxypropyl methylcellulose (HPMC), ethylcellulose (EC), hydroxyethylcellulose (HEC), sodium carboxymethyl-cellulose (CMC), dimethylaminoethyl methacrylate-methacrylic acid ester copolymer, ethylacrylate-methylmethacrylate copolymer (GA-MMA), C-5 or 60 SH-50 (Shin-Etsu Chemical Corp.), cellulose acetate phthalate (CAP), cellulose acetate trimelletate (CAT), poly(vinyl acetate) phthalate (PVAP), hydroxypropylmethylcellulose phthalate (HPMCP), poly(methacrylate ethylacrylate) (1:1) copolymer (MA-EA), poly(methacrylate methylmethacrylate) (1:1) copolymer (MA-MMA), poly(methacrylate methylmethacrylate) (1:2) copolymer, Eudragit L-30-D™ (MA-EA, 1:1), Eudragit L-100-55™ (MA-EA, 1:1), hydroxypropylmethylcellulose acetate succinate (HPMCAS), Coateric™ (PVAP), Aquateric™ (CAP), and AQUACOAT™ (HPMCAS), polycaprolactone, starches, pectins; polysaccharides such as tragacanth, gum arabic, guar gum, and xanthan gum.
(49) The stabilizing and non-solubilizing carrier may also contain various functional excipients, such as: hydrophilic polymer, antioxidant, super-disintegrant, surfactant including amphiphillic molecules, wetting agent, stabilizing agent, retardant, similar functional excipient, or combination thereof, and plasticizers including citrate esters, polyethylene glycols, PG, triacetin, diethylphthalate, castor oil, and others known to those or ordinary skill in the art. Extruded material may also include an acidifying agent, adsorbent, alkalizing agent, buffering agent, colorant, flavorant, sweetening agent, diluent, opaquant, complexing agent, fragrance, preservative or a combination thereof.
(50) Exemplary hydrophilic polymers which can be a primary or secondary polymeric carrier that can be included in the composites or composition disclosed herein include poly(vinyl alcohol) (PVA), polyethylene-polypropylene glycol (e.g. POLOXAMER™), carbomer, polycarbophil, or chitosan. Hydrophilic polymers for use with the present disclosure may also include one or more of hydroxypropyl methylcellulose, carboxymethylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methylcellulose, natural gums such as gum guar, gum acacia, gum tragacanth, or gum xanthan, and povidone. Hydrophilic polymers also include polyethylene oxide, sodium carboxymethycellulose, hydroxyethyl methyl cellulose, hydroxymethyl cellulose, carboxypolymethylene, polyethylene glycol, alginic acid, gelatin, polyvinyl alcohol, polyvinylpyrrolidones, polyacrylamides, polymethacrylamides, polyphosphazines, polyoxazolidines, poly(hydroxyalkylcarboxylic acids), carrageenate alginates, carbomer, ammonium alginate, sodium alginate, or mixtures thereof.
(51) By “immediate release” is meant a release of an active agent to an environment over a period of seconds to no more than about 30 minutes once release has begun and release begins within no more than about 2 minutes after administration. An immediate release does not exhibit a significant delay in the release of drug.
(52) By “rapid release” is meant a release of an active agent to an environment over a period of 1-59 minutes or 0.1 minute to three hours once release has begun and release can begin within a few minutes after administration or after expiration of a delay period (lag time) after administration.
(53) As used herein, the term “extended release” profile assumes the definition as widely recognized in the art of pharmaceutical sciences. An extended release dosage form will release the drug (i.e., the active agent or API) at a substantially constant rate over an extended period of time or a substantially constant amount of drug will be released incrementally over an extended period of time. An extended release tablet generally effects at least a two-fold reduction in dosing frequency as compared to the drug presented in a conventional dosage form (e.g., a solution or rapid releasing conventional solid dosage forms).
(54) By “controlled release” is meant a release of an active agent to an environment over a period of about eight hours up to about 12 hours, 16 hours, 18 hours, 20 hours, a day, or more than a day. By “sustained release” is meant an extended release of an active agent to maintain a constant drug level in the blood or target tissue of a subject to which the device is administered.
(55) The term “controlled release”, as regards to drug release, includes the terms “extended release”, “prolonged release”, “sustained release”, or “slow release”, as these terms are used in the pharmaceutical sciences. A controlled release can begin within a few minutes after administration or after expiration of a delay period (lag time) after administration.
(56) A slow release dosage form is one that provides a slow rate of release of drug so that drug is released slowly and approximately continuously over a period of 3 hr, 6 hr, 12 hr, 18 hr, a day, 2 or more days, a week, or 2 or more weeks, for example.
(57) The term “mixed release” as used herein refers to a pharmaceutical agent that includes two or more release profiles for one or more active pharmaceutical ingredients. For example, the mixed release may include an immediate release and an extended release portion, each of which may be the same API or each may be a different API.
(58) A timed release dosage form is one that begins to release drug after a predetermined period of time as measured from the moment of initial exposure to the environment of use.
(59) A targeted release dosage form generally refers to an oral dosage form that is designed to deliver drug to a particular portion of the gastrointestinal tract of a subject. An exemplary targeted dosage form is an enteric dosage form that delivers a drug into the middle to lower intestinal tract but not into the stomach or mouth of the subject. Other targeted dosage forms can deliver to other sections of the gastrointestinal tract such as the stomach, jejunum, ileum, duodenum, cecum, large intestine, small intestine, colon, or rectum.
(60) By “delayed release” is meant that initial release of drug occurs after expiration of an approximate delay (or lag) period. For example, if release of drug from an extended release composition is delayed two hours, then release of the drug begins at about two hours after administration of the composition, or dosage form, to a subject. In general, a delayed release is opposite of an immediate release, wherein release of drug begins after no more than a few minutes after administration. Accordingly, the drug release profile from a particular composition can be a delayed-extended release or a delayed-rapid release. A “delayed-extended” release profile is one wherein extended release of drug begins after expiration of an initial delay period. A “delayed-rapid” release profile is one wherein rapid release of drug begins after expiration of an initial delay period.
(61) A pulsatile release dosage form is one that provides pulses of high active ingredient concentration, interspersed with low concentration troughs. A pulsatile profile containing two peaks may be described as “bimodal.” A pulsatile profile of more than two peaks may be described as multi-modal.
(62) A pseudo-first order release profile is one that approximates a first order release profile. A first order release profile characterizes the release profile of a dosage form that releases a constant percentage of an initial drug charge per unit time.
(63) A pseudo-zero order release profile is one that approximates a zero-order release profile. A zero-order release profile characterizes the release profile of a dosage form that releases a constant amount of drug per unit time.
(64) The resulting composites or compositions disclosed herein may also be formulated to exhibit enhanced dissolution rate of a formulated poorly water soluble drug.
(65) An example of a composition or formulation having a stable release profile follows. Two tablets having the same formulation are made. The first tablet is stored for one day under a first set of conditions, and the second tablet is stored for four months under the same first set of conditions. The release profile of the first tablet is determined after the single day of storage and the release profile of the second tablet is determined after the four months of storage. If the release profile of the first tablet is approximately the same as the release profile of the second tablet, then the tablet/film formulation is considered to have a stable release profile.
(66) Another example of a composition or formulation having a stable release profile follows. Tablets A and B, each comprising a composition according to the present disclosure, are made, and Tablets C and D, each comprising a composition not according to the present disclosure, are made. Tablets A and C are each stored for one day under a first set of conditions, and tablets B and D are each stored for three months under the same first set of conditions. The release profile for each of tablets A and C is determined after the single day of storage and designated release profiles A and C, respectively. The release profile for each of tablet B and D is determined after the three months of storage and designated release profiles B and D, respectively. The differences between release profiles A and B are quantified as are the differences between release profiles C and D. If the difference between the release profiles A and B is less than the difference between release profiles C and D, tablets A and B are understood to provide a stable or more stable release profile.
(67) Specifically, the TKC process can be used for one or more of the following pharmaceutical applications.
(68) Dispersion of one or more APIs, wherein the API is a small organic molecule, protein, peptide, or polynucleic acid; in polymeric and/or non-polymeric pharmaceutically acceptable materials for the purpose of delivering the API to a patient via oral, pulmonary, parenteral, vaginal, rectal, urethral, transdermal, or topical routes of delivery.
(69) Dispersion of one or more APIs, wherein the API is a small organic molecule, protein, peptide, or polynucleic acid; in polymeric and/or non-polymeric pharmaceutically acceptable materials for the purpose of improving the oral delivery of the API by improving the bioavailability of the API, extending the release of the API, targeting the release of the API to specific sites of the gastrointestinal tract, delaying the release of the API, or producing pulsatile release systems for the API.
(70) Dispersion of one or more APIs, wherein the API is a small organic molecule, protein, peptide, or polynucleic acid; in polymeric and/or non-polymeric pharmaceutically acceptable materials for the purpose of creating bioerodable, biodegradable, or controlled release implant delivery devices.
(71) Producing solid dispersions of thermolabile APIs by processing at low temperatures for very brief durations.
(72) Producing solid dispersions of APIs in thermolabile polymers and excipients by processing at low temperatures for very brief durations.
(73) Rendering a small organic API amorphous while dispersing in a polymeric, non-polymeric, or combination excipient carrier system.
(74) Dry milling of crystalline API to reduce the particle size of the bulk material.
(75) Wet milling of crystalline API with a pharmaceutically acceptable solvent to reduce the particle size of the bulk material.
(76) Melt milling of a crystalline API with one or more molten pharmaceutical excipients having limited miscibility with the crystalline API to reduce the particle size of the bulk material.
(77) Milling crystalline API in the presence of polymeric or non-polymeric excipient to create ordered mixtures where fine drug particles adhere to the surface of excipient particles and/or excipient particles adhere to the surface of fine drug particles.
(78) Producing heterogeneously homogenous composites or amorphous composites of two or more pharmaceutical excipients for post-processing, e.g., milling and sieving, which are subsequently utilized in secondary pharmaceutical operations well known to those of skill in the art, e.g., film coating, tableting, wet granulation and dry granulation, roller compaction, hot melt extrusion, melt granulation, compression molding, capsule filling, and injection molding.
(79) Producing single phase, miscible composites of two or more pharmaceutical materials previously considered to be immiscible for utilization in a secondary processing step, e.g. melt extrusion, film coating, tableting and granulation.
(80) Pre-plasticizing polymeric materials for subsequent use in film coating or melt extrusion operations.
(81) Rendering a crystalline or semi-crystalline pharmaceutical polymer amorphous, which can be used as a carrier for an API in which the amorphous character improves the dissolution rate of the API-polymer composite, the stability of the API-polymer composite, and/or the miscibility of the API and the polymer.
(82) Deaggregate and disperse engineered particles in a polymeric carrier without altering the properties of the engineered particles.
(83) Simple blending of an API in powder form with one or more pharmaceutical excipients.
(84) Producing composites comprising one or more high melting point APIs and one or more thermolabile polymers without the use of processing agents.
(85) Homogenously dispersing a coloring agent or opacifying agent within a polymer carrier or excipient blend.
(86) In the following detailed description of preferred embodiments of the present disclosure, reference is made to the figures in the drawings, in which the same numeral refers to an identical or similar part in different figures.
(87) The present disclosure is directed to a novel thermokinetic mixer and mixing process that can blend heat sensitive or thermolabile components without substantial thermal degradation. In particular, the disclosure is useful in processing mixtures that include thermolabile components whose exposure to a melt temperature or a cumulative heat input over a defined time period results in degradation. One embodiment of present disclosure is directed to a method for a continuous melt blend of an autoheated mixture in the mixing chamber of a high speed thermokinetic mixer, where a first speed is changed mid-process to a second speed upon achieving a first desired or predetermined process parameter. In other embodiments, the second speed is changed mid-process to a third speed upon achieving a second desired or predetermined process parameter. Additional speed changes are also within the scope of the present disclosure, as dictated by the number of desired or predetermined processing parameters needed to produce the desired composition or composite.
(88) This process is especially applicable for producing solid dispersions of thermolabile APIs by processing at low temperatures for very brief durations at multiple speeds, producing solid dispersions of APIs in thermolabile polymers and excipients by processing at low temperatures for very brief durations at multiple speeds, producing solid dispersions of APIs in thermolabile excipients by processing at low temperatures for very brief durations at multiple speeds, and producing solid dispersions of heat sensitive polymers by processing at low temperatures for relatively brief durations at multiple speeds.
(89) One embodiment is to use two or more different speeds during thermokinetic processing of a batch to reduce required processing time after a shear transition temperature of a portion of the batch is reached. Another embodiment is to use two or more different speeds during thermokinetic processing of a batch to reduce required processing time where the batch reaches a temperature whereafter a substantial amount of heat generated by frictional contact with shaft extensions and/or an inside surface of the mixing chamber produces thermal degradation of one or more components of the batch, and reducing the speed. Yet a further embodiment is to use two or more different speeds during thermokinetic processing of a batch to reduce required processing time where the batch reaches a temperature whereafter a substantial amount of heat generated by frictional contact with shaft extensions and/or an inside surface of the mixing chamber does not result in an overall temperature change for the batch. Yet a further embodiment is to provide a thermokinetic processing method using two speeds to reduce thermal degradation of thermolabile or heat sensitive polymers or components of a batch processed thereby.
(90) In one embodiment, at least a portion of a batch in the mixing chamber of the high speed mixer comprises heat sensitive or thermolabile components whose exposure to a limit temperature or limit of cumulative heat input over a defined time period must be substantially prevented or limited to obtain a melt blended batch with acceptable degradation of the heat sensitive or thermolabile components. In this embodiment, at least one of the speed changes between a start and end of the process is made so that the limit temperature or limit of heat input is not exceeded, thereby preserving the heat sensitive or thermolabile components in the composition or composite.
(91) Thermolabile components include, but are not limited to, thermolabile APIs, excipients or polymers. Heat sensitive polymers include, but are not limited to, nylon, polytrimethylene terephthalate, polybutene-1, polybutylene terephthalate, polyethylene terephthalate, polyolefins such as polypropylene and high-density or low-density polyethylene, and mixtures or copolymers thereof, which polymers can be subject to surface and bulk polymer deficiencies as well as extrusion limitations. Other heat sensitive polymers include poly (methylmethacrylate), polyacetal, polyionomer, EVA copolymer, cellulose acetate, hard polyvinylchloride and polystyrene or copolymers thereof. A limit temperature in the disclosed process for such heat sensitive polymers may be chosen by maintaining sensed temperature of a batch within an acceptable range from the well known degradation temperature for that polymer, such as about 5, 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 degrees Celsius from a temperature at which it is known in the art that heat sensitive polymers begin to undergo degradation of a desired process parameter.
(92) One embodiment of the present disclosure is a method for continuous blending and melting of an autoheated mixture in the mixing chamber of a high speed mixer, where a first speed is changed mid-processing to a second speed upon achieving a first desired or predetermined process parameter. In one embodiment, the second speed is maintained until a final desired or predetermined process parameter is achieved, whereupon shaft rotation is stopped and a melt blended batch is withdrawn or ejected from the mixing chamber for further processing. The shaft operates at one or more intermediate rotational speeds between changing to the second speed and stopping the shaft rotation. Process parameters which determine shaft speed changes are predetermined and may be sensed and displayed, calculated, inferred, or otherwise established with reasonable certainty so that the speed change(s) is made during a single, rotationally continuous processing of a batch in a mixing chamber of the high speed mixer. Process parameters include without limitation temperature, motor RPM, amperage draw, and time.
(93) This disclosure is also directed to a thermokinetic mixer that can blend heat sensitive or thermolabile components without substantial thermal degradation. One embodiment of the thermokinetic mixer has a high horsepower motor driving the rotation of a horizontal shaft with teeth-like protrusions that extend outward normal to the rotational axis of the shaft. The shaft is connected to a drive motor. The portion of the shaft containing the protrusions is contained within an enclosed vessel where the compounding operation takes place, i.e., a thermokinetic mixing chamber. The high rotational velocity of the shaft coupled with the design of the shaft protrusions imparts kinetic energy onto the materials being processed. A temperature sensor senses the temperature within the thermokinetic mixing chamber. Once a set temperature is sensed, a first speed is changed to a second speed.
(94)
(95)
(96) In an example of a system in which the process parameters that determine shaft speed changes are measured in the mixing chamber and/or drive motor,
(97) A description of components of one embodiment of a thermokinetic mixer for the disclosed process is shown in
(98) With a typical batch process, a user will first select two components, which could include, for example, a thermolabile API and a polymer excipient. The user will then empirically determine the shear transition temperatures of the two components. The user will then set the process parameters (temperature, RPM, amperage draw, and time) in the programmable logic controller to change from the first speed to the second speed as is suitable for the shear transition temperatures of the components. Any of the setpoints entered by the user can be used as a stop point following the period of the second speed.
(99)
(100) In
(101) The same batch and thermokinetic mixer in
(102)
(103) It is well known in the art that impact of a particle on a surface imparts energy to the particle. It is a feature of thermokinetic, auto-heating mixers to provide impact on a particle containing polymers whereby imparted energy is translated partly into heat energy to soften and/or melt those polymers. However, the thermokinetic mixing art generally directs those skilled in the art to provide impact for particles in thermokinetic mixers in a manner that lacks fine control of translation of impact energy into heat energy. The present disclosure provides for and describes methods for such control. Highly cross-linked polymers and thermoset compounds are highly refractory to softening and melting for the same reason they are preferred, i.e., they resist breaking down. Yet, they are shown to be of value in some combinations of components processed with thermokinetic mixing. Indeed, thermokinetic mixing is essentially the only way to process highly cross-linked polymers and thermosets due to their resistance to melting and blending in any other manner. In the thermokinetic mixing art, increasing rotational shaft speed and/or processing time were understood to be the method by which melt-resistant polymers could be induced to translate sufficient impact energy to heat energy to effect a softened or molten state for further processing. The present embodiment discloses an apparatus and methods by which impact energy translation to heat energy can be effectively controlled.
(104) Two primary impact surfaces, the front face and the top face of a shaft, control impact translation to heat energy in a thermokinetic mixer. Those two surfaces are the facial portions of the shaft extensions that intrude into the outer 30 percent or less of volume of the mixing chamber (the volume is referred to hereafter as the “main processing volume”; it includes a most restricted zone of about one inch inward radius from the inside cylindrical wall of the mixing chamber) and the inside cylindrical surface of the mixing chamber itself. Changing the inside cylindrical surface of the mixing chamber is not a practical option—that surface, being stationary, must remain smooth and cylindrically uniform to resist buildup of molten materials and to allow for skidding and sliding autoheating contact with particles being moved through the mixing chamber.
(105) The present disclosure uses variations in the top face of the shaft extensions that intrude into the main processing volume to control translation of rotational shaft energy delivered to the extensions into heating energy within particles impacting the portions. It has been found that varying the width and angle away from a shaft axis plane for the main facial portion provides a controllable variation in shear delivered to a particle impacting the portion, which in turn provides control over shaft energy translated into heat energy available for softening or melting a polymer part of a particle in a thermokinetic mixing chamber.
(106) Referring again to
(107) For these specific comparisons of the operation of thermokinetic mixers with several configurations of a main facial portion, it is assumed that energy input through the shaft and the shaft rotational speed is about the same and that the number of shaft extensions and their spacing along the length of the shaft within the mixing chamber is substantially the same. Thus, the comparisons will show the effect of changing the shapes of the main facial portion.
(108) In general, decreasing the width relative to the length of the main facial portion increases shaft energy translated into heat energy available for softening or melting a polymer part of a particle in a thermokinetic mixing chamber. The width must be above a minimum contact width so that a particle experiences a sliding impact along the width, the particle is induced into a “skid” or energy imparting frictional contact, rolling and sliding at the period of time for impact on the portion. Mere normal glancing impact of a particle on a surface is relatively ineffective in imparting thermokinetic, autoheating energy for softening or melting. Yet, easily melted and heat-labile or heat sensitive polymers in some cases are sometimes processed with a main facial portion providing just such glancing impact to provide more control over heat application to such components. Consistent with this teaching, polymers refractory or resistant to softening or melting by application of heat are often processed with a main facial portion of minimum width (at least 0.25 inches) aligned at a minimum angle back from a shaft axial plane (for example, at least 10 degrees or at least 15 degrees) providing a contact time for essentially the same energy input, whereby distribution of that energy into skidding and rotational motion improves autoheating of the particle's polymer content.
(109) A design of a shaft extension currently found in the Draiswerke Gelimat® thermokinetic mixer has the cross section 50 shown in
(110)
(111) Thus, the shear strength of polymers processed by way of thermokinetic, autoheating mixing and blending can now be matched to the relative shear energy imparted by the shaft extensions in the mixing chamber. A further design refinement is desirable where, as is quite common, polymer components in a batch comprise both high shear and low shear polymers. Providing a main facial portion suited for a high shear component imparts shear energy which may deliver too much heat energy to low shear components. In such a case, the low shear component tends to soften and roll along the width of the main facial portion, further increasing the heat generated, while the high shear components tend to leave that surface more readily. Such a circumstance could tend to cause incomplete mixing with the high shear components insufficiently melted or overheating of low shear components. There is yet a further need for designs of a main facial portion that achieve an optimal shear delivery to high and low shear components in a thermokinetic batch.
(112) It has been found that increasing the width of the main facial portion achieves this optimization. At an angle of between 15 to 80 degrees from a shaft axis plane, and the main facial portion having a width of at least 0.75 inches, provides sufficient path travel for both high and low shear polymer components in a batch so that the high shear components remain in sliding and skidding contact with the main facial portion long enough to generate heat and absorb heat from lower shear components to become softened and thereby blend with the low shear components.
(113) Alternate designs for the main facial portion are shown in
(114) In light of the above teaching of these embodiments, the top face 22 of
(115)
(116) In a further embodiment of the present disclosure whereby materials or texturing of liner pieces 5a, 7a and 6a are selected to obtain the objects of thermokinetic mixing, shaft extension portions comprising the front and top impact faces of the shaft extensions are adapted by way of material composition and/or texturing similar to those changes just disclosed for the inside surfaces of liner pieces 5a, 7a and 6a.
(117) Another feature of the present disclosure is that the top face of the shaft extensions, i.e., those which extend at least with a slight elevation rearward above the height of the front face of the shaft extension to form a ramp structure upon which chambered particles impinge (faces 22 of
(118)
(119)
(120) In certain embodiments, a shaft extension providing a relatively long frictional contact path for particles being processed by the mixer of the present disclosure are preferred for providing shortened processing times, i.e., to heat a batch to a desired temperature as quickly as possible. Such control of heating and processing times is directly applicable to the disclosed process of two step continuous thermokinetic mixing, whereby increasing rotational shaft speed will more swiftly impart frictional heating for melting energy to the particles more refractory or resistant to lower speed heating. It has been found that non-uniformity of materials in a batch processed thermokinetically, i.e., either by composition or particle size, results in greater or lesser frictional path contact with the insides of the mixing chamber. Particles more resistant to melting, either by way of higher melting temperatures or hardness, will rebound more quickly from frictional contact with the inside surfaces of a thermokinetic mixer and thereby require more processing time than less refractory particles. Thermokinetic mixing to a final, desired processing consistency for heat labile or heat damageable components generally favors reaching a target batch temperature as quickly as possible. Certain embodiments of the present disclosure provide short, medium, long or mixed lengths of particle frictional contact paths along a top face of a shaft extension, either by way of a single or multiple processing shaft speeds, to achieve the more effective mixing of certain thermolabile components.
(121) It is well known to those in the art that the topmost surfaces of shaft extensions in the Draiswerke mixers are merely arcuately tapered and smoothed ends of a generally sinous shaft extension. As such, the ability of such mixers to provide substantial top face shearing, frictional heating to thermokinetic mixing chamber particles is essentially minimized. To accomplish additional top face-like frictional paths for particles in the mixing chamber and to accomplish other objects of the present disclosure,
DETAILED DESCRIPTION OF THE INVENTION FOR THE FIRST AND SECOND EMBODIMENTS
(122)
(123) Additional information about the physical and thermal changes that occur in the first and second embodiments is now described.
(124) In a slow second stage embodiment of the invention, it is preferred that a first stage be completed at plateau detection followed by a second stage at a lower shaft speed, whereby a final required reduction of crystalline form pharmaceutical or drug is accomplished at a reduced shear and friction intensity. The following are components for which the slow second stage embodiment have been found successfully applied: [pharmaceutical and excipient/carrier names].
(125) A subtle difference in the effects of thermokinetic mixing on the component combination must be appreciated as to a first step of a lower shaft speed and a second step of a higher shaft speed. It is now clear that the lower shaft speed step provides an amount of heat almost instantly at from 9-11 s. (
(126) Elimination of the long plateau period, where degradation can occur of desired drugs or pharmaceuticals, is a primary object of the first and second embodiments, where degradation of even 0.2 percent of a desired pharmaceutical or drug can render a thermokinetically mixed batch not usable. In a specific example, one component combination required 18 seconds of a single, low speed thermokinetic mixing, where, by using a pre-determined temperature increase rate as a trigger setpoint as the end of the first stage period to start a second stage of higher shaft speed, the required entire process time was 8 seconds. It is preferable that the second, higher shaft speed is from 20 to 100 percent greater than a first, lower shaft speed and more preferable that the second, higher shaft speed is from 40 to 80 percent greater than a first, lower shaft speed.
(127) Further, in general the pharmaceutical or drug of a component combination is a small molecule as compared with its excipient, where the smaller, amorphous molecule of the drug acts essentially as a “lubricant” for the much larger polymer. The energy input per unit of component combination is not high enough to complete a desired change from crystalline to amorphous structure until the “lubricant” drug is captured into the molten or “sticky” larger polymer aggregations. A useful analogy is that creating solid dispersions is like dissolving a drug in a liquid. To help the drug dissolve faster, either the temperature or the stirring rate should be increased. It was unpredictable that such a significant effect could be obtained in the first or second embodiments by detection of a process point at which the motor shaft speed should be increased to prevent drug degradation.
(128) Returning to the first embodiment using a temperature increase rate as a trigger setpoint, is fixed so that it passes through a port in mixing chamber MC with a distal end pointing generally toward the shaft supporting the shaft extensions, where another end of sensor 20 is connected to a batch microprocessor BMCRO. Batch microprocessor BMCRO (comprising a CPU, a memory, a clock, and an input/output unit, all operating under under a batch control program) receives sensed temperature signals from sensor 20 and stores them its memory correlated to a recording time a predetermined intervals (preferably from 500 to 5 ms.), whereupon the batch control program causes the stored temperature and recorded time data to be used to calculate a rate of temperature change over a period of time from 2 s. to 10 ms. using an arithmetical average, differential rate of change calculation, or other averaging calculation method. A when a calculated rate of temperature change is determined to equal or to approach a predetermined trigger value of rate of temperature change stored in the memory, the batch control program acts immediately or with some delay to send a signal to a speed controller of motor 15 to increase a lower shaft rotation speed to a higher shaft rotation speed, preferably for a predetermined period of time, whereafter the batch control program acts to cause motor 15 to stop.
(129)
(130) For the first embodiment, the mixer control microprocessor continuously calculates from temperature trigger data a temperature rate of increase and stores those values in memory, calculating certain rates at step 106. The mixer control microprocessor comprises either a pre-stored value of a trigger setpoint of a temperature increase rate or a trigger setpoint calculated by obtaining a maximum rate of increase over a previous period of time (which is preferably between 0.5 s. and 1.0 s.) and calculating a trigger setpoint as a temperature rate of increase which is substantially less than that trigger setpoint.
(131) For the second embodiment, the mixer control microprocessor continuously stores crystallinity values detected in the mixing chamber as trigger data and optionally at step 106 calculates a crystallinity rate of decrease and stores those values in memory. The mixer control microprocessor comprises either a pre-stored value of a trigger setpoint of a crystallinity value or a crystallinity decrease rate as a trigger setpoint.
(132) At step 108, the mixer control program microprocessor determines if a trigger setpoint has been reached by trigger data or their calculated rates. If that state occurs, the mixer microprocessor acts to either increase shaft speed after a first stage period and to stop mixing at the end of a second stage period.
(133) Among many methods of calculation of an increase temperature rate for the first embodiment, one preferred method is to detect and store a sensed temperature of the mixing batch from 30 to 0.5 ms and to calculate an average of each preceding 5 to 10 recorded batch temperature values. Trigger setpoints of from 1.5 to 0 degrees per second are preferred for the first embodiment, where a maximum temperature increase rate is not being used to determine the trigger setpoint.
(134) For a trigger setpoint for the second embodiment, an absolute value of from 20 to 0 percent crystallinity is preferred, more preferred is from 2-0 percent detected crystallinity of the pharmaceutical or drug being measured. A trigger setpoint for a rate of crystallinity decrease is preferably from 20 percent per second to 0 percent per second.
(135) For the first embodiment, a stop point for thermokinetic mixing for a specific component combination is determined by trial, where acceptable low or non-existent levels of crystallinity are found and degradation of the drug or pharmaceutical is within acceptable limits. For the second embodiment, a stop point for thermokinetic mixing for a specific component combination is determined by trial, where acceptable low or non-existent levels of crystallinity are found and degradation of the drug or pharmaceutical is within acceptable limits or by a pre-determined low level of detected crystallinity.
(136)
(137)
(138)
(139) All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.